株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

抗真菌薬の世界市場の分析:機会と予測

Global Antifungal Drugs Market: Analysis By Drug Class, By Therapeutic Indications, By Region, By Country - Opportunities and Forecast 2013-2023

発行 Azoth Analytics 商品コード 781871
出版日 ページ情報 英文 240 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.55円で換算しております。
Back to Top
抗真菌薬の世界市場の分析:機会と予測 Global Antifungal Drugs Market: Analysis By Drug Class, By Therapeutic Indications, By Region, By Country - Opportunities and Forecast 2013-2023
出版日: 2019年01月31日 ページ情報: 英文 240 Pages
概要

当レポートでは、世界の抗真菌薬市場について調査分析し、統計と情報 (市場規模・シェア・成長要因) のほか、新興動向、主要促進要因、課題と機会、主要企業について、体系的な情報を提供しています。

第1章 調査手法

第2章 エグゼクティブサマリー

第3章 戦略的提言

第4章 抗真菌薬製品の見通し

第5章 世界の抗真菌薬市場:成長率と予測

  • 金額別 (実績)
  • 金額別 (予測)

第6章 世界の抗真菌薬市場:セグメント別分析

  • 薬剤分類別:内訳
    • アゾール
    • エキノカンジン
    • ポリエン
    • その他
  • 市場の魅力
  • 治療適応別:内訳
    • アスペルギルス症
    • 皮膚糸状菌症 (白癬)
    • カンジダ症
    • その他

第7章 世界の抗真菌薬市場:地域別分析

  • 地域別:内訳

第8章 北米の抗真菌薬市場:分析

  • セグメント別分析
  • 薬剤分類別:内訳
  • 治療適応別:内訳
  • 国別分析

第9章 欧州の抗真菌薬市場:分析

  • セグメント別分析
  • 薬剤分類別:内訳
  • 治療適応別:内訳
  • 国別分析

第10章 アジア太平洋地域の抗真菌薬市場:分析

  • セグメント別分析
  • 薬剤分類別:内訳
  • 治療適応別:内訳
  • 国別分析

第11章 その他の地域の抗真菌薬市場:成長率と予測

  • セグメント別分析
  • 薬剤分類別:内訳
  • 治療適応別:内訳

第12章 世界の抗真菌薬市場:市場力学

  • 市場促進要因
  • 市場抑制要因
  • 市場動向

第13章 ファイブフォース分析

第14章 SWOT分析

第15章 抗真菌薬市場:競合情勢

第16章 企業プロファイル

  • Merck & Co.
  • Pfizer
  • GSK
  • Novartis
  • Abbott Laboratories
  • Astellas Pharma
  • Bayer
  • Sanofi
  • Kramer Laboratories
図表

List of Figures

  • Figure 1: Global Antifungal Drugs Market Size, By Value, 2013-2017 (USD Million)
  • Figure 2: Number of People Living With HIV, 2013-2017
  • Figure 3: Number of New Cases of Cancer, In 2018, By Type, (% of Total)
  • Figure 4: Estimated TB Incidences, By WHO Regions, 2016
  • Figure 5: Prevalence of Diagnosed Autoimmune Diseases, In 2018, By Selected Countries, (% of Total)
  • Figure 6: Burden of Antifungal Infections, By Type
  • Figure 7: Generic Market Value Share, In 2006 (Left) &2016 (Right), By Region
  • Figure 8: Global Prescription and OTC Drugs Sales, 2013-2017, (USD Billion)
  • Figure 9: Expected Global Medical Spending in 2020, By Product Type, (% of Total)
  • Figure 10: Expected Global Medical Spending in 2020, By Region, (% of Total)
  • Figure 11: Global Aged Population (Above 65), 2013-2017 (% of total)
  • Figure 12: Global Aged Population(Above 65), By Country, 2017 (% of total)
  • Figure 13: Healthcare Expenditure (Share of GDP), By Selected Country, 2013-2017 (In %)
  • Figure 14: GDP Per Capita PPP, By Region, 2018 (in Thousand USD)
  • Figure 15: Global Expected Healthcare Industry Outlook
  • Figure 16: Regional Expected Healthcare Industry Growth Rate By Year 2020
  • Figure 17: Global Antifungal Drugs Market Size, By Value, Forecast, 2018-2023 (USD Million)
  • Figure 18: Global Antifungal Drugs Market Size, By Drug Class, 2017 (%)
  • Figure 19: Global Antifungal Drugs Market Size, By Drug Class, 2023F (%)
  • Figure 20: Global Azoles Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 21: Global Azoles Antifungal Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 22: Global Echinocandins Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 23: Global Echinocandins Antifungal Drugs Market, 2018-2023(USD Million)
  • Figure 24: Global Polyenes Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 25: Global Polyenes Antifungal Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 26: Global Other Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 27: Global Other Antifungal Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 28: Market Comparison Chart, By Product Type, 2013-2023 (USD Million)
  • Figure 29: Global Market Attractiveness, By Product Type, 2023F
  • Figure 30: Global Antifungal Drugs Market Size, By Therapeutic Indications , 2017 (%)
  • Figure 31: Global Antifungal Drugs Market Size, By Therapeutic Indications , 2023F (%)
  • Figure 32: Global Antifungal Drugs Market, By Therapeutic Indications , By Value, 2013-2017 (USD Million)
  • Figure 33: Global Antifungal Drugs Market, By Therapeutic Indications , By Value, 2018-2023(USD Million)
  • Figure 34: Global Antifungal Drugs Market Size, By Region, 2017 (%)
  • Figure 35: Global Antifungal Drugs Market Size, By Region, 2023F (%)
  • Figure 36: North America Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 37: United States Spending on Medicines, 2013-2017 (In USD Billion)
  • Figure 38: Patented and Non-Patented Drugs Sales in Canada, 2013-2016 (USD Billion)
  • Figure 39: North America Diseases Outlook
  • Figure 40: United States health care expenditure per capita,2013-2016(USD)
  • Figure 41: Canada health care expenditure per capita,2013-2016(USD)
  • Figure 42: North America population aged 65 and above, 2013-2017 (% of total)
  • Figure 43: North America Healthcare Cost Per Capita, 2017 (USD)
  • Figure 44: North America GDP per Capita, 2013-2017 (USD)
  • Figure 45: North America Antifungal Drugs Market, By Value, 2018-2023 (USD Million)
  • Figure 46: North America Antifungal Drugs Market Size, By Drug Class, 2017 (%)
  • Figure 47: North America Antifungal Drugs Market Size, By Drug Class, 2023F (%)
  • Figure 48: North America Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
  • Figure 49: North America Antifungal Drugs Market Size, By Therapeutic Indications , 2017 (%)
  • Figure 50: North America Antifungal Drugs Market Size, By Therapeutic Indications , 2023F (%)
  • Figure 51: North America Antifungal Drugs Market, By Therapeutic Indications , By Value, 2013-2017 (USD Million)
  • Figure 52: North America Antifungal Drugs Market, By Therapeutic Indications , By Value, 2013-2017 (USD Million)
  • Figure 53: North America Antifungal Drugs Market, By Therapeutic Indications , By Value, 2013-2017 (USD Million)
  • Figure 54: North America Antifungal Drugs Market Size, By Countries, 2023F (%)
  • Figure 55: USA Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 56: USA Antifungal Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 57: United States Fungal Infection Facts & Figures
  • Figure 58: New Patients Diagnosed with HIV in 2017, By Age Group
  • Figure 59: United States Per Capita Spending on Medicines, 2013-2017 (In USD)
  • Figure 60: Pharmacy & Drug Store Sales in United States, 2013-2016 (In USD Billion)
  • Figure 61: Medical and Healthcare Research & Development Spending, 2013-2016 (In USD Million)
  • Figure 62: U.S., Population ages 65 and above, 2013-2017 (% of total)
  • Figure 63: U.S., Population ages 65 and above, Forecast (In Millions)
  • Figure 64: U.S., Per Capita Expenditure on Healthcare, 2012-2018E (In USD)
  • Figure 65: U.S., GDP (Current USD), 2013-2017 (In USD Trillion)
  • Figure 66: USA Antifungal Drugs Market Size, By Drug Class, 2017 (%)
  • Figure 67: USA Antifungal Drugs Market Size, By Drug Class, 2023F (%)
  • Figure 68: USA Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
  • Figure 69: USA Antifungal Drugs Market Size, By Therapeutic Indications , 2017 (%)
  • Figure 70: USA Antifungal Drugs Market Size, By Therapeutic Indications , 2017 (%)
  • Figure 71: USA Antifungal Drugs Market, By Therapeutic Indications , By Value, 2013-2017 (USD Million)
  • Figure 72: USA Antifungal Drugs Market, By Therapeutic Indications , By Value, 2018-2023(USD Million)
  • Figure 73: Leading Antifungal Drugs Companies In The United States of America
  • Figure 74: Canada Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 75: Canada Antifungal Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 76: Estimated Number of Serious Fungal Infections Cases in Canada, 2014
  • Figure 77: Estimated Number of Mucosal Candidiasis in Canada, 2014
  • Figure 78: Estimated Number of Opportunistic Invasive Fungal Infections Cases in Canada, 2014
  • Figure 79: Estimated Number of Endemic Mycoses Cases in Canada, 2014
  • Figure 80: Estimated Number of Non-Invasive Pulmonary Aspergillosis Cases in Canada, 2014
  • Figure 81: Number of Retail Pharmacies in Canada, 2013-2017
  • Figure 82: Number of Hospitals Establishments in Canada, By Province, 2015
  • Figure 83: Number HIV Cases in Canada, 2013-2016
  • Figure 84: Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %)
  • Figure 85: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
  • Figure 86: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
  • Figure 87: Canada Antifungal Drugs Market Size, By Drug Class, 2017 (%)
  • Figure 88: Canada Antifungal Drugs Market Size, By Drug Class, 2023F (%)
  • Figure 89: Canada Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
  • Figure 90: Canada Antifungal Drugs Market Size, By Therapeutic Indications , 2017 (%)
  • Figure 91: Canada Antifungal Drugs Market Size, By Therapeutic Indications , 2023F (%)
  • Figure 92: Canada Antifungal Drugs Market, By Therapeutic Indications , By Value, 2013-2017 (USD Million)
  • Figure 93: Canada Antifungal Drugs Market, By Therapeutic Indications , By Value, 2018-2023(USD Million)
  • Figure 94: Leading Antifungal Drugs Companies In Canada
  • Figure 95: Europe Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 96: Europe Health Expenditure, By Select Country, 2016 (% of GDP)
  • Figure 97: Europe Population ages 65 years and above (% of total population), 2013-17
  • Figure 98: Europe, Fungal Infections Burden, (Per 100000 population), By Selected Countries
  • Figure 99: Europe Antifungal Drugs Market, By Value, 2018-2023 (USD Million)
  • Figure 100: Europe Antifungal Drugs Market Size, By Drug Class, 2017 (%)
  • Figure 101: Europe Antifungal Drugs Market Size, By Drug Class, 2023F (%)
  • Figure 102: Europe Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
  • Figure 103: Europe Antifungal Drugs Market Size, By Therapeutic Indications , 2017 (%)
  • Figure 104: Europe Antifungal Drugs Market Size, By Therapeutic Indications , 2023F (%)
  • Figure 105: Europe Antifungal Drugs Market, By Therapeutic Indications , By Value, 2013-2017 (USD Million)
  • Figure 106: Europe Antifungal Drugs Market, By Therapeutic Indications , By Value, 2018-2023(USD Million)
  • Figure 107: Europe Antifungal Drugs Market Size, By Countries, 2017 (%)
  • Figure 108: Europe Antifungal Drugs Market Size, By Countries, 2023F (%)
  • Figure 109: Germany Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 110: Germany Antifungal Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 111: Germany, Healthcare Related Statistics, 2017
  • Figure 112: Germany, Leukemia Incidences, 2014 & 2018E
  • Figure 113: Germany, Population ages 65 and above, 2012-2017 (% total)
  • Figure 114: Germany, Cause of Deaths, Percentage Change ,2007-2017
  • Figure 115: Germany, Cause of Deaths, Percentage Change ,2007-2017
  • Figure 116: Germany, HIV Prevalence, 2013-2017
  • Figure 117: Germany, Prevalence of Cancer, 2018 (% of total)
  • Figure 118: Germany Antifungal Drugs Market Size, By Drug Class, 2017 (%)
  • Figure 119: Germany Antifungal Drugs Market Size, By Drug Class, 2023F (%)
  • Figure 120: Germany Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
  • Figure 121: Germany Antifungal Drugs Market Size, By Therapeutic Indications , 2017 (%)
  • Figure 122: Germany Antifungal Drugs Market Size, By Therapeutic Indications , 2023F (%)
  • Figure 123: Germany Antifungal Drugs Market, By herapeutic Indications , By Value, 2013-2017 (USD Million)
  • Figure 124: Germany Antifungal Drugs Market, By herapeutic Indications , By Value, 2013-2017 (USD Million)
  • Figure 125: Leading Antifungal Drugs Companies In Germany
  • Figure 126: France Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 127: France Antifungal Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 128: France, Healthcare Infrastructure Related Statistics
  • Figure 129: France, Health Expenditure, (% of GDP), 2012-2015 (USD)
  • Figure 130: France, Population Ages 65 and Above (% of total), 2012-2017
  • Figure 131: France, Prevalence of Cancer, 2018, (% of total)
  • Figure 132: France, Spending on Healthcare, 2015 & 2040$, (USD Per Person)
  • Figure 133: France Antifungal Drugs Market Size, By Drug Class, 2017 (%)
  • Figure 134: France Antifungal Drugs Market Size, By Drug Class, 2023F (%)
  • Figure 135: France Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
  • Figure 136: France Antifungal Drugs Market Size, By Therapeutic Indications , 2017 (%)
  • Figure 137: France Antifungal Drugs Market Size, By Therapeutic Indications , 2023F (%)
  • Figure 138: France Antifungal Drugs Market, By Therapeutic Indications , By Value, 2013-2017 (USD Million)
  • Figure 139: France Antifungal Drugs Market, By Therapeutic Indications , By Value, 2018-2023(USD Million)
  • Figure 140: Leading Antifungal Drugs Companies In France
  • Figure 141: U.K Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 142: U.K Antifungal Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 143: U.K, Health Expenditure, (% of GDP), 2013-2017 (USD)
  • Figure 144: U.K, Population Ages 65 and Above (% of total), 2012-2017
  • Figure 145: UK, Prevalence of Cancer, 2018, (% of Total)
  • Figure 146: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person)
  • Figure 147: UK, Healthcare Infrastructure Related Statistics
  • Figure 148: Candidaemia per 100,000 population by region (England, Wales and Northern Ireland), 2013-2017
  • Figure 149: U.K Antifungal Drugs Market Size, By Drug Class, 2017 (%)
  • Figure 150: U.K Antifungal Drugs Market Size, By Drug Class, 2023F (%)
  • Figure 151: U.K Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
  • Figure 152: U.K Antifungal Drugs Market Size, By Therapeutic Indications , 2017 (%)
  • Figure 153: U.K Antifungal Drugs Market Size, By Therapeutic Indications , 2023F (%)
  • Figure 154: U.K Antifungal Drugs Market, By Therapeutic Indications , By Value, 2013-2017 (USD Million)
  • Figure 155: U.K Antifungal Drugs Market, By Therapeutic Indications , By Value, 2018-2023(USD Million)
  • Figure 156: Leading Antifungal Drugs Companies In U.K
  • Figure 157: APAC Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 158: GDP Per Capita in APAC, By Select Country, 2016 (In USD)
  • Figure 159: Population ages 65 and above, By Select Country, 2017 (% of total)
  • Figure 160: Cancer Incidences in Asia, (% of Total), 2018
  • Figure 161: China, Pharmaceuticals Industry Revenue (USD Billion)
  • Figure 162: Japan, Total Drugs Market, 2013-2017, USD Billion
  • Figure 163: India Pharma Market, 2015-2017, (USD Billion)
  • Figure 164: APAC Antifungal Drugs Market, By Value, 2018-2023 (USD Million)
  • Figure 165: APAC Antifungal Drugs Market Size, By Drug Class, 2017 (%)
  • Figure 166: APAC Antifungal Drugs Market Size, By Drug Class, 2023F (%)
  • Figure 167: APAC Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
  • Figure 168: APAC Antifungal Drugs Market Size, By Therapeutic Indications , 2017 (%)
  • Figure 169: APAC Antifungal Drugs Market Size, By Therapeutic Indications , 2023F (%)
  • Figure 170: APAC Antifungal Drugs Market, By Therapeutic Indications , By Value, 2013-2017 (USD Million)
  • Figure 171: APAC Antifungal Drugs Market, By Therapeutic Indications , By Value, 2018-2023(USD Million)
  • Figure 172: APAC Antifungal Drugs Market Size, By Countries, 2017 (%)
  • Figure 173: APAC Antifungal Drugs Market Size, By Countries, 2023F (%)
  • Figure 174: China Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 175: China Antifungal Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 176: China, Fungal Infections Facts & Figures
  • Figure 177: China, Number of HIV Patients
  • Figure 178: China, Cancer Incidences ( in Million)
  • Figure 179: China, GDP Growth Per Year, 2015-2019 (In %)
  • Figure 180: China, Share of Urban Population, 2012-2017 (In %)
  • Figure 181: China, Total Population, 2013-2021F (In Billion)
  • Figure 182: China Antifungal Drugs Market Size, By Drug Class, 2017 (%)
  • Figure 183: China Antifungal Drugs Market Size, By Drug Class, 2023F (%)
  • Figure 184: China Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
  • Figure 185: China Antifungal Drugs Market Size, By Therapeutic Indications , 2017 (%)
  • Figure 186: China Antifungal Drugs Market Size, By Therapeutic Indications , 2023F (%)
  • Figure 187: China Antifungal Drugs Market, By Therapeutic Indications , By Value, 2013-2017 (USD Million)
  • Figure 188: China Antifungal Drugs Market, By Therapeutic Indications , By Value, 2018-2023(USD Million)
  • Figure 189: Leading Antifungal Drugs Companies In China
  • Figure 190: Japan Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 191: Japan Antifungal Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 192: Japan, Population ages 65 and above, 2012-2017 (% of total)
  • Figure 193: Japan, HIV Prevalence, 2017
  • Figure 194: Japan, Medical Facilities Outlook
  • Figure 195: Japan Healthcare Expenditure Outlook (%)
  • Figure 196: Japan, GDP Growth Per Year, 2015-2019F (In %)
  • Figure 197: Japan, Population ages 65 and above, 2012-2016 (% of total)
  • Figure 198: Japan Antifungal Drugs Market Size, By Drug Class, 2017 (%)
  • Figure 199: Japan Antifungal Drugs Market Size, By Drug Class, 2023F (%)
  • Figure 200: Japan Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
  • Figure 201: Japan Antifungal Drugs Market Size, By Therapeutic Indications , 2017 (%)
  • Figure 202: Japan Antifungal Drugs Market Size, By Therapeutic Indications , 2023F (%)
  • Figure 203: Japan Antifungal Drugs Market, By Therapeutic Indications , By Value, 2013-2017 (USD Million)
  • Figure 204: Japan Antifungal Drugs Market, By Therapeutic Indications , By Value, 2018-2023 (USD Million)
  • Figure 205: Leading Antifungal Drugs Companies In Japan
  • Figure 206: India Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 207: India Antifungal Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 208: India, Fungal Infection Facts & Figures
  • Figure 209: India, Diseases & Medical Industry Outlook
  • Figure 210: India, Population ages 65 and above, 2013-2017
  • Figure 211: India, Total Population, 2013-2023F (In Billion)
  • Figure 212: Pharma Export From India Market, 2013-2017, (USD Billion)
  • Figure 213: India Antifungal Drugs Market Size, By Drug Class, 2017 (%)
  • Figure 214: India Antifungal Drugs Market Size, By Drug Class, 2023F (%)
  • Figure 215: India Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
  • Figure 216: India Antifungal Drugs Market Size, By Therapeutic Indications , 2017 (%)
  • Figure 217: India Antifungal Drugs Market Size, By Therapeutic Indications , 2023F (%)
  • Figure 218: India Antifungal Drugs Market, By Therapeutic Indications , By Value, 2013-2017 (USD Million)
  • Figure 219: India Antifungal Drugs Market, By Therapeutic Indications , By Value, 2018-2023(USD Million)
  • Figure 220: Leading Antifungal Drugs Companies In India
  • Figure 221: ROW Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 222: Fungal Infection Burden in Latin America & Egypt, By Selected Countries
  • Figure 223: HIV Prevalence in LA&C and MENA (% of total), 2018
  • Figure 224: Cancer Prevalence in MENA (% of total), 2018
  • Figure 225: Cancer Prevalence in Latin America & Caribbean , (% of total), 2018
  • Figure 226: GDP Per Capita in ROW, By Select Country, 2013 (In USD)
  • Figure 227: GDP Per Capita in ROW, By Select Country, 2017 (In USD)
  • Figure 228: Latin America and Caribbean, Population ages 65 and above 2012-2017(% of total)
  • Figure 229: Middle East and North Africa, Population ages 65 and above (% of total)
  • Figure 230: ROW Antifungal Drugs Market, By Value, 2018-2023 (USD Million)
  • Figure 231: ROW Antifungal Drugs Market Size, By Drug Class, 2017 (%)
  • Figure 232: ROW Antifungal Drugs Market Size, By Drug Class, 2023F (%)
  • Figure 233: ROW Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
  • Figure 234: ROW Antifungal Drugs Market Size, By Therapeutic Indications , 2017 (%)
  • Figure 235: ROW Antifungal Drugs Market Size, By Therapeutic Indications , 2023F (%)
  • Figure 236: ROW Antifungal Drugs Market,By Therapeutic Indications , By Value, 2013-2017 (USD Million)
  • Figure 237: ROW Antifungal Drugs Market, By Therapeutic Indications , By Value, 2018-2023(USD Million)
  • Figure 238: Branded Antifungal Drugs Sales, 2017, (USD Million)
  • Figure 239: Merck & Co., Revenues 2013-2017(USD Million)
  • Figure 240: Merck & Co., Revenues, By Region, 2017(% of Total)
  • Figure 241: Merck & Co., Revenues, By Region, 2017(% of Total)
  • Figure 242: Pfizer, Net Sales, 2013-2017 (USD Million)
  • Figure 243: Pfizer, Revenue, By Segments, 2017 (%)
  • Figure 244: Vfend, Net Sales, 2015-2017 (USD Million)
  • Figure 245: GSK, Revenues, 2013-2017 (USD Million)
  • Figure 246: GSK, Revenue, By Region, 2017 (USD Million)
  • Figure 247: GSK, Revenue, By Segments, 2017(%)
  • Figure 248: GSK, Revenue, By Pharmaceuticals Segment, 2017 (USD Million)
  • Figure 249: Novartis, Net Sales, 2013-2017 (USD Million)
  • Figure 250: Novartis, Revenue, By Segment, 2017(%)
  • Figure 251: Novartis, Revenue, By Region, 2017(%)
  • Figure 252: Abbott Laboratories, Net Sales, 2013-2017 (USD Million)
  • Figure 253: bbott Laboratories, Revenue, By Segments, 2017(%)
  • Figure 254: Abbott Laboratories, Revenue, By Regions, 2017(%)
  • Figure 255: Astellas, Net Sales, 2013-2017 (USD Million)
  • Figure 256: Astellas, Revenue, By Regions, 2017(%)
  • Figure 257: Astellas, Revenue, By Segments, 2017(%)
  • Figure 258: Bayer, Net Sales, 2013-2017 (USD Million)
  • Figure 259: Bayer, Net Sales, 2013-2017 (USD Million)
  • Figure 260: Bayer, Revenue, By Segments, 2017(%)
  • Figure 261: Sanofi, Net Sales, 2013-2017 (USD Million)
  • Figure 262: Bio-Rad Revenue, By Region, 2017(%)

List of Tables

Table 1: Different Types of Common Fungal Diseases

Table 2: Different Class of Anti-Fungal Drugs

Table 3: Common Invasive Fungal Diseases and Their Treatment Options

Table 4: Common Invasive Fungal Diseases and Their Treatment Options

Table 5: Burden of Fungal Diseases

Table 6: Antifungal Compounds in Development Stage - By Phases

Table 7: EU-5 Socio-Economical Statistics, 2017

Table 8: Germany, Fungal Infection Burden

Table 9: France, Fungal Infection Burden

Table 10: Invasive Fungal Infection Burden In UK

Table 11: Estimated Antifungal Prevalence in Japan, 2016

Table 12: Percentage aged 60 years and over, (2000, 2015, 2030,2050)

Table 13: Competitive Landscape - Leading Companies - Sales by Drug Class

目次

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Antifungal Drugs Market. The report analyses the Antifungal Drugs Market By Drug Type (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others). The report analyses the Antifungal Drugs Market, By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S., Canada, Germany, U.K, France, China, Japan, India) for the historical period of 2013-2017 and the forecast period of 2018-2023.

According to Azoth Analytics research report "Global Antifungal Drugs Market: Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others), By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, Asia Pacific, ROW), By Country (U.S., Canada, Germany, U.K, France, China, Japan, India)", the antifungal drugs market is projected to display a robust growth represented by a CAGR of 3.70% during 2018 - 2023.

Over the recent years, Antifungal Drugs market has been witnessing growth on account of several driving factors including growing prevalence of fungal infections such as candidiasis and aspergillosis, increasing popularity of over-the-counter drugs, and increase in availability of innovative antifungals. Moreover, increasing awareness regarding fatal antifungal diseases, growing medical spending, favorable government initiatives, public private partnership have been driving the market growth. In addition, rising geriatric population, increasing global healthcare expenditure and technological advancements in pharmaceuticals research, growing scope in developing countries with large population such as China and India is anticipated to impel the market growth of the antifungal drugs market. However, growing portfolio of antifungal generic drugs, patent expiration of innovator drugs, increasing prevalence of fungal resistance, and counterfeit drugs are expected to hinder the market performance during forecasted period.

In this research report, the market is segmented on the basis of drug class and therapeutic indications. By drug class, the azoles class antifungals are predicted to hold their dominant position in the market. By therapeutic indications, drugs use in the treatment of candidiasis are anticipated to creates their dominance in global antifungal drugs market. Amongst the regions, North America accounts for the largest regional share in the global antifungal drugs market in 2017. The largest share of North America is attributed to presence of enormous number of patient base and highly advanced medical infrastructure.

The report titled "Global Antifungal Drugs Market: Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others), By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, Asia Pacific, ROW), By Country (U.S., Canada, Germany, U.K, France, China, Japan, India)", has covered and analysed the potential of antifungal drugs market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the antifungal drugs. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Antifungal Drugs Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)

  • Antifungal Drugs Market- Size, Growth, Forecast
  • Analysis By Drug Type - Azole Class Antifungal Drugs, Echinocandins Class Antifungal Drugs, Polyenes Class Antifungal Drugs, Other Class Antifungal Drugs
  • Analysis By Therapeutic Indications - Aspergillus, Dermatophytosis, Candidiasis, Other Therapeutic Indications

Regional Antifungal Drugs Market - North America, Europe, Asia Pacific, Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)

  • Antifungal Drugs Market- Size, Growth, Forecast
  • Analysis By Drug Type - Azole Class Antifungal Drugs, Echinocandins Class Antifungal Drugs, Polyenes Class Antifungal Drugs, Other Class Antifungal Drugs
  • Analysis By Therapeutic Indications - Aspergillus, Dermatophytosis, Candidiasis, Other Therapeutic Indications

Country Analysis - U.S., Canada, Germany, U.K, France, China, Japan, India (Actual Period: 2013-2017, Forecast Period: 2018-2023)

  • Antifungal Drugs Market- Size, Growth, Forecast
  • Analysis By Drug Type - Azole Class Antifungal Drugs, Echinocandins Class Antifungal Drugs, Polyenes Class Antifungal Drugs, Other Class Antifungal Drugs
  • Analysis By Therapeutic Indications - Aspergillus, Dermatophytosis, Candidiasis, Other Therapeutic Indications

Other Report Highlights

  • Market Dynamics - Drivers and Restraints.
  • Market Trends.
  • Porter Five Forces Analysis.
  • SWOT Analysis.
  • Company Analysis - Merck & Co., Glaxo Smith Kline, Astellas Pharma, Sanofi, Abbott Laboratories, Bayer, Kramer Laboratories, Novartis International AG, Pfizer.

Customization of the Report

The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.

Table of Contents

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. Antifungal Drugs Products Outlook

5. Global Antifungal Drugs Market: Growth and Forecast

  • 5.1 By Value (2013-2017)
  • 5.2 By Value (2018-2023)

6. Global Antifungal Drugs Market: Segmental Analysis

  • 6.1 Global Antifungal Drugs Market Size, By Drug Class: Breakdown (%)
    • 6.1.1 Global Antifungal Drugs Market Size, By Drug Class, 2017 (%)
    • 6.1.2 Global Antifungal Drugs Market Size, By Drug Class, 2023 (%)
  • 6.2 Global Azole Class Antifungal Drugs Market Size, By Value (2013-2023)
  • 6.3 Global Echinocandins Class Antifungal Drugs Market Size, By Value (2013-2023)
  • 6.4 Global Polyenes Antifungal Drugs Market Size, By Value (2013-2023)
  • 6.5 Global Other Antifungal Drugs Market Size, By Value (2013-2023)
  • 6.6 Global Antifungal Drugs: Market Attractiveness, By Drug Class
  • 6.7 Global Antifungal Drugs Market Size, By Therapeutic Indications : Breakdown(%)
    • 6.7.1 Global Aspergillus Antifungal Drugs Market Size, By Value (2013-2023)
    • 6.7.2 Global Dermatophytosis Antifungal Drugs Market Size, By Value (2013-2023)
    • 6.7.3 Global Candidiasis Antifungal Drugs Market Size, By Value (2013-2023)
    • 6.6.2 Global Other Therapeutic Indications Antifungal Drugs Market Size, By Value (2013-2023)

7. Global Antifungal Drugs Market: Regional Analysis

  • 7.1 Global Antifungal Drugs Market Size, By Region : Breakdown (%)
    • 7.1.1 Global Antifungal Drugs Market Size, By Region, 2017 (%)
    • 7.1.2 Global Antifungal Drugs Market Size, By Region, 2023 (%)

8. North America Antifungal Drugs Market: An Analysis

  • 8.1 North America Antifungal Drugs Market: Segment Analysis
  • 8.2 North America Antifungal Drugs Market Size, By Drug Class: Breakdown (%)
    • 8.2.1 North America Antifungal Drugs Market Size, By Drug Class, 2017 (%)
    • 8.2.2 North America Antifungal Drugs Market Size, By Drug Class, 2023 (%)
  • 8.3 North America Azoles Antifungal Drugs Market Size, By Value (2013-2023)
  • 8.4 North America Echinocandins Antifungal Drugs Market Size, By Value (2013-2023)
  • 8.5 North America Polyenes Antifungal Drugs Market Size, By Value (2013-2023)
  • 8.6 North America Others Antifungal Drugs Market Size, By Value (2013-2023)
  • 8.7 North America Antifungal Drugs Market Size, By Therapeutic Indications : Breakdown(%)
    • 8.7.1 North America Aspergillus Antifungal Drugs Size, By Value (2013-2023)
    • 8.7.2 North America Dermatophytosis Antifungal Drugs Market Size, By Value (2013-2023)
    • 8.7.3 North America Candidiasis Antifungal Drugs Size, By Value (2013-2023)
    • 8.7.4 North America Other Therapeutic Indications Antifungal Drugs Market Size, By Value (2013-2023)
  • 8.8 North America Antifungal Drugs Market: Country Analysis (U.S and Canada)
    • 8.8.1 U.S Antifungal Drugs Market, By Value (2013-2023)
    • 8.8.2 U.S Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
    • 8.8.3 U.S Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
    • 8.8.4 Canada Antifungal Drugs Market, By Value (2013-2023)
    • 8.8.5 Canada Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
    • 8.8.6 Canada Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)

9. Europe Antifungal Drugs Market: An Analysis

  • 9.1 Europe Antifungal Drugs Market: Segmental Analysis
  • 9.2 Europe Antifungal Drugs Market Size, By Drug Class: Breakdown (%)
    • 9.1.2 Europe Antifungal Drugs Market Size, By Drug Class, 2017 (%)
    • 9.1.3 Europe Antifungal Drugs Market Size, By Drug Class, 2023 (%)
  • 9.3 Europe Azoles Antifungal Drugs Market Size, By Value (2013-2023)
  • 9.4 Europe Echinocandins Drugs Market Size, By Value (2013-2023)
  • 9.5 Europe Polyenes Antifungal Drugs Market Size, By Value (2013-2023)
  • 9.6 Europe Antifungal Drugs Market Size, By Therapeutic Indications : Breakdown(%)
    • 9.6.1 Europe Aspergillosis Antifungal Drugs Market Size, By Value (2013-2023)
    • 9.6.2 Europe Dermatophytosis Antifungal Drugs Market Size, By Value (2013-2023)
    • 9.6.3 Europe Candidiasis Antifungal Drugs Market Size, By Value (2013-2023)
    • 9.6.4 Europe Other Therapeutic Indications Antifungal Drugs Market Size, By Value (2013-2023)
  • 9.7 Europe Antifungal Drugs Market: Country Analysis (Germany, France, Italy, U.K)
    • 9.7.1 Germany Antifungal Drugs Market, By Value (2013-2023)
    • 9.7.2 Germany Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
    • 9.7.3 Germany Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
    • 9.7.4 France Antifungal Drugs Market, By Value (2013-2023)
    • 9.7.5 France Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
    • 9.7.6 France Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
    • 9.7.7 UK Antifungal Drugs Market, By Value (2013-2023)
    • 9.7.8 UK Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
    • 9.7.9 UK Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)

10. APAC Antifungal Drugs Market: An Analysis

  • 10.1 APAC Antifungal Drugs Market: Segmental Analysis
  • 10.2 APAC Antifungal Drugs Market Size, By Drug Class: Breakdown (%)
    • 10.2.1 APAC Antifungal Drugs Market Size, By Drug Class, 2017 (%)
    • 10.2.2 APAC Antifungal Drugs Market Size, By Drug Class, 2023 (%)
  • 10.3 APAC Azole Antifungal Drugs Market Size, By Value (2013-2023)
  • 10.4 APAC Echinocandins Antifungal Drugs Market Size, By Value (2013-2023)
  • 10.5 APAC Polyenes Antifungal Drugs Market Size, By Value (2013-2023)
  • 10.6 APAC Other Antifungal Drugs Market Size, By Value (2013-2023)
  • 10.7 APAC Antifungal Drugs Market Size, By Therapeutic Indications : Breakdown(%)
    • 10.7.1 APAC Aspergillosis Antifungal Drugs Market Size, By Value (2013-2023)
    • 10.7.2 APAC Dermatophytosis Antifungal Drugs Market Size, By Value (2013-2023)
    • 10.7.3 APAC Candidiasis Antifungal Drugs Market Size, By Value (2013-2023)
    • 10.7.4 APAC Other Therapeutic Indications Antifungal Drugs Market Size, By Value (2013-2023)
  • 10.8 APAC Antifungal Drugs Market: Country Analysis (China, Japan, and India)
    • 10.8.1 China Antifungal Drugs Market, By Value (2013-2023)
    • 10.8.2 China Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
    • 10.8.3 China Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
    • 10.8.4 Japan Antifungal Drugs Market, By Value (2013-2023)
    • 10.8.5 Japan Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
    • 10.8.6 Japan Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
    • 10.8.7 India Antifungal Drugs Market, By Value (2013-2023)
    • 10.8.8 India Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
    • 10.8.9 India Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)

11. ROW Antifungal Drugs Market: Growth and Forecast

  • 11.1 ROW Antifungal Drugs Market: Segmental Analysis
  • 11.2 ROW Antifungal Drugs Market Size, By Drug Class: Breakdown (%)
    • 11.1.1 ROW Antifungal Drugs Market Size, By Drug Class, 2017 (%)
    • 11.1.2 ROW Antifungal Drugs Market Size, By Drug Class, 2023 (%)
  • 11.3 ROW Azole Antifungal Drugs Market Size, By Value (2013-2023)
  • 11.4 ROW Echinocandins Antifungal Drugs Market Size, By Value (2013-2023)
  • 11.5 ROW Polyenes Antifungal Drugs Market Size, By Value (2013-2023)
  • 11.6 ROW Other Antifungal Drugs Market Size, By Value (2013-2023)
  • 11.7 ROW Antifungal Drugs Market Size, By Therapeutic Indications : Breakdown(%)
    • 11.7.1 ROW Aspergillosis Antifungal Drugs Market Size, By Value (2013-2023)
    • 11.7.2 ROW Dermatophytosis Antifungal Drugs Market Size, By Value (2013-2023)
    • 11.7.3 ROW Candidiasis Antifungal Drugs Market Size, By Value (2013-2023)
    • 11.7.4 ROW Other Therapeutic Indications Antifungal Drugs Market Size, By Value (2013-2023)

12. Global Antifungal Drugs Market: Market Dynamics

  • 12.1 Global Antifungal Drugs Market Drivers
  • 12.2 Global Antifungal Drugs Market Restrains
  • 12.3 Global Antifungal Drugs Market Trends

13. Porter Five Force Analysis

14. SWOT Analysis

15. Antifungal Drugs Market - Competitive Landscape

16. Company Profiles

  • 16.1 Merck & Co.
  • 16.2 Pfizer
  • 16.3 GSK
  • 16.4 Novartis
  • 16.5 Abbott Laboratories
  • 16.6 Astellas Pharma
  • 16.7 Bayer
  • 16.8 Sanofi
  • 16.9 Kramer Laboratories
Back to Top